GM-CSF Inhalation for Refractory NTM Infection Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pulmonary non-tuberculous mycobacteria (NTM) infections are often refractory, requiring long courses of antibiotics that are poorly tolerated and have low success rates, with many patients experiencing side effects and recurrence of the disease.
Innovation Solution
Administration of granulocyte-macrophage colony stimulating factor (GM-CSF) or its functional homologues via pulmonary routes, such as inhalation, to treat NTM infections refractory to antibiotic treatment, enhancing the body's immune response and lung defense mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If antibiotic treatment is used for NTM infections, then bacterial load is reduced, but treatment tolerance deteriorates due to severe side effects
Solution Approach 1:
The patent introduces GM-CSF as an intermediary substance that mediates the immune system's response to NTM bacteria. Instead of directly attacking bacteria with antibiotics (which cause side effects), GM-CSF stimulates the body's own immune cells (macrophages and neutrophils) to eliminate the bacteria, thereby reducing treatment tolerance issues while maintaining antibacterial efficacy
2Duration of action of moving object
If long-course antibiotic treatment is administered, then treatment coverage is improved, but treatment complexity increases
Solution Approach 1:
The patent enables the patient's immune system to serve itself by stimulating endogenous macrophage and neutrophil activity through GM-CSF administration. This self-service mechanism allows the body to continuously fight the infection without requiring prolonged external antibiotic intervention, thereby reducing treatment complexity while maintaining adequate treatment coverage
3Reliability
If traditional antibiotic therapy is used, then initial treatment effect is achieved, but long-term reliability deteriorates due to high recurrence rates
Solution Approach 1:
The patent applies preliminary action by enhancing the immune system's capacity before and during the infection process. By administering GM-CSF to stimulate macrophage and neutrophil function in advance and throughout treatment, the body is better prepared to eliminate bacteria and prevent recurrence, thereby improving both initial treatment effect and long-term disease control reliability
Data Source
AI summary
The present invention relates to methods of treating subjects suffering from a pulmonary NTM infection refractory to treatment, for example to antibiotic treatment.